Physician profile
Congling Wang
NPI 1760081244
$1,886.79
in general payments reported to CMS, 2019-2025
14 companies · $1,060 in 2025
The $1,060 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $195 · 2023: $88.38 · 2024: $543 · 2025: $1,060.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,692.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,691.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $288.12 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.23 | 2025 | Jardiance |
| Amgen INC. | $226.00 | 2024-2025 | Krystexxa |
| Abbott Laboratories | $153.43 | 2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $134.99 | 2025 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $124.40 | 2025 | |
| Sk Life Science, INC. | $124.10 | 2024 | Xcopri |
| Ultragenyx Pharmaceutical INC. | $120.00 | 2022 | |
| Grifols USA, LLC | $115.75 | 2025 | Prolastin-C Liquid |
| Alnylam Pharmaceuticals INC. | $107.87 | 2025 | Amvuttra |
| Exeltis, USA INC. | $103.35 | 2025 | Slynd, Twirla |
| Biogen, INC. | $83.26 | 2024 | Skyclarys |
| Abbvie INC. | $61.09 | 2022 | |
| Novo Nordisk INC | $14.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Congling Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.